Table 3b.

In Vivo treatment scheme of PDOX models.

Compounds	Name in the study	Target	Solution for compounds	Treatment scheme in PDOX model	Route of administration
Alvocidib	Flavopiridol	CDK9 kinase inhibitor	1 mg/mL in 0.2 mL DMSO add 14.8 mL PBS	5 mg/kg/day ×12 days	i.p.
Alisertib	MLN8237	Aurora A Kinase inhibitor	5 mg/mL in 10% HPBCD/1% sodium bicarbonate	30 mg/kg/day x 12 days	gavage
NA	Radiation	DNA	NA	2 Gy/day x 5 days	In located brain
Temozolomide	TMZ	Alkylate/methylate DNA	In water	50 mg/kg/day ×5 day	gavage
Panobinostat	Panobinostat	HDACi	2 mg/mL in DMSO (1.3%)/DPBS	10 mg/kg (5 d on-2 d off) x 2 cycle	i.p.
Valproic acid	VPA	HDACi	In 0.9% sodium chloride solution	600 mg/mL x 7 days (1 μl/hr),	Pump
Suberoylanilide Hydroxamic Acid	SAHA	HDACi	In PBS/DMSO (1:1)	100 mg/kg, Qd, 2 weeks	i.p.
Veliparib	ABT888	PARPi inhibitor	In 2% DMSO	10μl/g ×5 days, Qd	i.p.
Cisplatin	Cisplatin	DNA	Sterile water	5 mL/kg on days 1 and 4	i.p.
Seneca Valley Virus	SVV-001	Oncolytic virus	In PBS	20μ1*10^8vp/ul for one time	Tail vein